Arcturus Therapeutics Holdings Inc. Overview

Arcturus Therapeutics Holdings Inc., a company based in San Diego, United States, operates within the health care sector as a holding company. The company is primarily engaged in the development of RNA therapeutics aimed at treating a variety of diseases. Arcturus Therapeutics serves patients exclusively within the United States and maintains an online presence through its website, www.arcturusrx.com . The company is listed on the Nasdaq stock exchange.

Recent Financial Performance

As of June 26, 2025, Arcturus Therapeutics Holdings Inc. reported a close price of $13.33. Over the past year, the company’s stock has experienced significant fluctuations. The 52-week high was recorded at $25.88 on October 1, 2024, while the 52-week low was $8.04, observed on April 6, 2025. These figures reflect the dynamic nature of the biotechnology sector and the market’s response to the company’s ongoing research and development efforts.

Company Focus and Operations

Arcturus Therapeutics Holdings Inc. is dedicated to advancing RNA therapeutics, a cutting-edge field in medical science that holds promise for treating a wide range of diseases. Through its subsidiaries, the company is actively involved in the research, development, and commercialization of RNA-based therapies. This focus positions Arcturus Therapeutics at the forefront of innovative treatments within the health care industry.

Market Presence

The company’s presence in the market is marked by its Nasdaq listing, which provides it with visibility and access to a broad investor base. Arcturus Therapeutics continues to engage with stakeholders through its online platform, ensuring transparency and accessibility for patients and investors alike.

In summary, Arcturus Therapeutics Holdings Inc. remains a key player in the health care sector, with a strong emphasis on RNA therapeutics. Despite recent stock volatility, the company’s commitment to innovation and patient care continues to drive its strategic initiatives.